Recent advances in the treatment of chronic hepatitis B

Expert Opinion on Pharmacotherapy

Volumn 12, Issue 13, 2011, Pages 2025-2040

  Lin, Chih Lin ^a   Kao, Jia Horng ^b  

^a TAIPEI CITY HOSPITAL   (Taiwan)

^b NATIONAL TAIWAN UNIVERSITY   (Taiwan)

Author keywords

antiviral therapy; chronic hepatitis B; drug resistant hepatitis B virus; nucleos(t)ide analogues; pegylated interferon

Indexed keywords

ADEFOVIR DIPIVOXIL; ALPHA2A INTERFERON; ALPHA2B INTERFERON; CREATININE; EMTRICITABINE; ENTECAVIR; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B(E) ANTIGEN; LAMIVUDINE; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; TELBIVUDINE; TENOFOVIR DISOPROXIL; VIRUS DNA;

ADD ON THERAPY; ANTIVIRAL RESISTANCE; ANTIVIRAL THERAPY; CLASSIFICATION ALGORITHM; CLINICAL TRIAL (TOPIC); COMBINATION CHEMOTHERAPY; CREATININE BLOOD LEVEL; DRUG EFFECT; DRUG EFFICACY; DRUG MONITORING; DRUG POTENCY; DRUG SUBSTITUTION; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; GENETIC VARIABILITY; GENOTYPE; HEPATITIS B; HEPATITIS B VIRUS; HOST; HUMAN; IMMUNOTHERAPY; MEDICAL DECISION MAKING; MONOTHERAPY; NEPHROTOXICITY; NONHUMAN; PERSONALIZED MEDICINE; PRACTICE GUIDELINE; REVIEW; SEROCONVERSION; SIDE EFFECT; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; VIRUS LOAD; VIRUS MUTANT; VIRUS MUTATION;

ANTIVIRAL AGENTS; HEPATITIS B, CHRONIC; HUMANS; INTERFERON-ALPHA; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 80051498209     PISSN: 14656566     EISSN: 17447666     Source Type: Journal    
DOI: 10.1517/14656566.2011.590474     Document Type: Review

References (131)

1. Fattovich G, Stroffolini T, Zagni I, Donato F. Hepatocellular carcinoma in cirrhosis: Incidence and risk factors. Gastroenterology 2004;12(Suppl 1):S35-50 (Pubitemid 39423368)
2. Kao JH. Hepatitis B virus genotypes and hepatocellular carcinoma in Taiwan. Intervirology 2003;46:400-7
3. Lok AS. Chronic hepatitis B. N Engl J Med 2002;346:1682-3
4. Lok AS, McMahon BJ. Chronic hepatitis B: Update 2009. Hepatology 2009;50:661-2 The practice guidelines for treatment of chronic hepatitis B developed by AASLD.
5. European Association for the Study of the Liver. EASL Clinical Practice Guidelines: Management of chronic hepatitis B. J Hepatol 2009;50:227-42 The practice guidelines for treatment of chronic hepatitis B developed by EASL.
6. Liaw YF, Leung N, Kao JH, et al. Asian-Pacific consensus statement on the management of chronic hepatitis B: A 2008 update. Hepatol Int 2008;2:263-83 The practice guidelines for treatment of chronic hepatitis B developed by APASL.
7. Dianzani F. Biological basis for the clinical use of interferon. Gut 1993;34(Suppl):S74-6 (Pubitemid 23156092)
8. Wong DK, Cheung AM, O'Rourke K, et al. Effect of alpha-interferon treatment in patients with hepatitis B e antigen-positive chronic hepatitis B. A meta-analysis. Ann Intern Med 1993;119:312-23 (Pubitemid 23319890)
9. Moucari R, Korevaar A, Lada O, et al. High rates of HBsAg seroconversion in HBeAg-positive chronic hepatitis B patients responding to interferon: A long-term follow-up study. J Hepatol 2009;50:1084-92
10. Cooksley WG. Treatment with interferons (including pegylated interferons) in patients with hepatitis B. Semin Liver Dis 2004;24(Suppl 1):45-53 (Pubitemid 38738358)
11. Brunetto MR, Oliveri F, Colombatto P, et al. Treatment of HBeAg-negative chronic hepatitis B with interferon or pegylated interferon. J Hepatol 2003;39(Suppl 1):S164-7 (Pubitemid 37222666)
12. Hadziyannis SJ. Treatment paradigms on hepatitis B e antigen negative chronic hepatitis B patients. Expert Opin Investig Drugs 2007;16:777-86 (Pubitemid 46882353)
13. Baker DE. Pegylated interferons. Rev Gastroenterolo Disord 2001;1:87-99
14. Craxi A, Cooksley WG, Pegylated interferons for chronic hepatitis B. Antiviral Res. 2003;60:87-9 (Pubitemid 37452451)
15. Cooksley WG, Piratvisuth T, Lee SD, et al. Peginterferon alpha-2a (40 kDa): An advance in the treatment of hepatitis B e antigen-positive chronic hepatitis B. J Viral Hepat 2003;10:298-305 (Pubitemid 36801917)
16. Lau GK, Piratvisuth T, Luo KX, et al. Peginterferon Alfa-2a, lamivudine and the combination for HBeAg-positive chronic hepatitis B. N Engl J Med 2005;352:2682-95 (Pubitemid 41007823)
17. Janssen HL, van Zonneveld M, Senturk H, et al. Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: A randomised trial. Lancet 2005;365:123-9 (Pubitemid 40091801)
18. Piratvisuth T, Lau G, Chao YC, et al. Sustained response to peginterferon alfa-2a (40 kD) with or without lamivudine in Asian patients with HBeAg-positive and HBeAg-negative chronic hepatitis B. Hepatol Int 2008;2:102-10 (Pubitemid 351250409)
19. Buster EH, Flink HJ, Cakaloglu Y, et al. Sustained HBeAg and HBsAg loss after long-term follow-up of HBeAg-positive patients treated with peginterferon alpha-2b. Gastroenterology 2008;135:459-67 A long-term follow-up study of the sustainability of HBeAg and HBsAg negativity in HBeAg-positive CHB patients treated with pegylated interferon a-2b.
20. Marcellin P, Lau GK, Bonino F, et al. Peginterferon Alfa-2a HBeAg-Negative Chronic Hepatitis B Study Group. Peginterferon alfa-2a alone, lamivudine alone and the two in combination in patients with HBeAg-negative chronic hepatitis B. N Engl J Med 2004;351:1206-17 (Pubitemid 39296307)
21. Marcellin P Piratvisuth T, Brunetto M, et al. Virological and biochemical response in patients with HBeAg-negative chronic hepatitis B treated with peginterferon alfa-2a (40KD) with or without lamivudine: Results of 4-year follow-up. J Hepatol 2008;48(Suppl 2):S46
22. Feld JJ, Wong DK, Heathcote EJ. Endpoints of therapy in chronic hepatitis B. Hepatology 2009;49:96-102
23. Lai CL, Chien RN, Leung NW, et al. A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group. N Engl J Med 1998;339:61-8 (Pubitemid 28304879)
24. Liaw YF, Leung NW, Chang TT, et al. Effects of extended lamivudine therapy in Asian patients with chronic hepatitis B. Asia Hepatitis Lamivudine Study Group. Gastroenterology 2000;119:172-80 (Pubitemid 30452590)
25. Leung NW, Lai CL, Chang TT, et al. Asia Hepatitis Lamivudine Study Group. Extended lamivudine treatment in patients with chronic hepatitis B enhances hepatitis B e antigen seroconversion rates: Results after 3 years of therapy. Hepatology 2001;33:1527-32 (Pubitemid 32496991)
26. Chang TT, Lai CL, Chien RN, et al. Four years of lamivudine treatment in Chinese patients with chronic hepatitis B. J Gastroenterol Hepatol 2004;19:1276-82
27. Guan R, Lai CL, Liaw YF, et al. Efficacy and safety of 5 years lamivudine treatment of Chinese patients with chronic hepatitis B (abstr). J Gastroenterol Hepatol 2001;16:A60
28. Dienstag JL, Goldin RD, Heathcote EJ, et al. Histological outcome during longterm lamivudine therapy. Gastroenterology 2003;124:105-17 (Pubitemid 36055344)
29. Hadziyannis SJ, Papatheodoridis GV, Dimou E, et al. Efficacy of long-term lamivudine monotherapy in patients with hepatitis B e antigen-negative chronic hepatitis B. Hepatology 2000;32:847-51
30. Lai CL, Shouval D, Lok AS, et al. BEHoLD AI463027 Study Group. Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B. N Engl J Med 2006;354:1011-20 (Pubitemid 43357805)
31. Lai CL, Gane E, Liaw YF, et al. Globe Study Group. Telbivudine versus lamivudine in patients with chronic hepatitis B. N Engl J Med 2007;357:2576-88 (Pubitemid 350294224)
32. Yao GB, Zhu M, Cui ZY, et al. A 7-year study of lamivudine therapy for hepatitis B virus e antigen-positive chronic hepatitis B patients in China. J Dig Dis 2009;10:131-7
33. Liaw YF. Impact of YMDD mutations during lamivudine therapy in patients with chronic hepatitis B. Antivir Chem Chemother 2001;12(Suppl 1):67-71
34. Papatheodoridis GV, Dimou E, Dimakopoulos K, et al. Outcome of hepatitis B e antigen-negative chronic hepatitis B on long-term nucleos(t)ide analog therapy starting with lamivudine. Hepatology 2005;42:121-9 (Pubitemid 40911319)
35. Zhang QQ, An X, Liu YH, et al. Long-term nucleos(t)ide analogues therapy for adults with chronic hepatitis B reduces the risk of long-term complications: A meta-analysis. Virol J 2011;8:72 A meta-analysis showing the reduced risk of complications including decompensated cirrhosis, liver-related death or HCC in CHB patients with long-term nucleos(t)ide analogues therapy.
36. Marcellin P, Chang TT, Lim SG, et al. Adefovir Dipivoxil 437 Study Group. Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. N Engl J Med 2003;348:808-16 (Pubitemid 36245757)
37. Marcellin P, Chang TT, Lim SG, et al. Long-term efficacy and safety of adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. Hepatology 2008;48:750-8
38. Hadziyannis SJ, Tassopoulos N, Heathcote EJ, et al. Adefovir Dipivoxil 438 Study Group. Adefovir dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis B. N Engl J Med 2003;348:800-7 (Pubitemid 36245756)
39. Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, et al. Adefovir Dipivoxil 438 Study Group. Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5 years. Gastroenterology 2006;131:1743-51 (Pubitemid 44958517)
40. Bridges EG. Telbivudine preclinical safety studies suggest minimal risk of chronic toxicity, reproductive toxicity or carcinogenicity. J Hepatol 2006;44(Suppl 2):S147
41. Liaw YF, Gane E, Leung N, et al. GLOBE Study Group. 2-Year GLOBE trial results: Telbivudine is superior to lamivudine in patients with chronic hepatitis B. Gastroenterology 2009;136:486-95
42. Wursthorn K, Jung M, Riva A, et al. Kinetics of hepatitis B surface antigen decline during 3 years of telbivudine treatment in hepatitis B e antigen-positive patients. Hepatology 2010;52:1611-20
43. Locarnini S. Primary resistance, multidrug resistance and cross-resistance pathways in HBV as a consequence of treatment failure. Hepatol Int 2008;2:147-51 (Pubitemid 351650142)
44. Lai CL, Rosmawati M, Lao J, et al. Entecavir is superior to lamivudine in reducing hepatitis B virus DNA in patients with chronic hepatitis B infection. Gastroenterology 2002;123:1831-8 (Pubitemid 35408307)
45. Baldick CJ, Tenney DJ, Mazzucco CE, et al. Comprehensive evaluation of hepatitis B virus reverse transcriptase substitutions associated with entecavir resistance. Hepatology 2008;47:1473-82 (Pubitemid 351702731)
46. Chang TT, Gish RG, de Man R, et al. BEHoLD AI463022 Study Group. A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B. N Engl J Med 2006;354:1001-10 (Pubitemid 43357804)
47. Chang TT, Lai CL, Kew Yoon S, et al. Entecavir treatment for up to 5 years in patients with hepatitis B e antigen-positive chronic hepatitis B. Hepatology 2010;51:422-30
48. Gish RG, Lok AS, Chang TT, et al. Entecavir therapy for up to 96 weeks in patients with HBeAg-positive chronic hepatitis B. Gastroenterology 2007;133:1437-44 (Pubitemid 350029745)
49. Gish RG, Chang TT, Lai CL, et al. Loss of HBsAg antigen during treatment with entecavir or lamivudine in nucleoside-naive HBeAg-positive patients with chronic hepatitis B. J Viral Hepat 2010;17:16-22
50. Chang TT, Liaw YF, Wu SS, et al. Long-term entecavir therapy results in the reversal of fibrosis/cirrhosis and continued histological improvement in patients with chronic hepatitis B. Hepatology 2010;52:886-93
51. Woo G, Tomlinson G, Nishikawa Y, et al. Tenofovir and entecavir are the most effective antiviral agents for chronic hepatitis B: A systematic review and Bayesian meta-analyses. Gastroenterology 2010;139:1218-29 A meta-analysis of randomized controlled trials evaluating the relative efficacies of 12 months of licensed antiviral therapies for treatment-naïve CHB patients.
52. Tenney DJ, Rose RE, Baldick CJ, et al. Long-term monitoring shows hepatitis B virus resistance to entecavir in nucleoside-naive patients is rare through 5 years of therapy. Hepatology 2009;49:1503-14
53. Marcellin P, Heathcote EJ, Buti M, et al. Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B. N Engl J Med 2008;359:2442-55
54. Marcellin P, Buti M, Krastev Z, et al. Continued efficacy and safety through 4 years of tenofovir disoproxil fumarate (TDF) treatment in HBeAg-negative patients with chronic hepatitis B (Study 102): Preliminary analysis. Hepatology 2010;52(Suppl):555A
55. Heathcote E, Gane EJ, deMan RA, et al. Long term (4 Year) efficacy and safety of tenofovir disoproxil fumarate (TDF) treatment in HBeAg-positive patients (HBeAg+) with chronic hepatitis B (Study 103): Preliminary analysis. Hepatology 2010;52(Suppl):556A
56. Herlitz LC, Mohan S, Stokes MB, et al. Tenofovir nephrotoxicity: Acute tubular necrosis with distinctive clinical, pathological and mitochondrial abnormalities. Kidney Int 2010;78:1171-7
57. Hoofnagle JH, Doo E, Liang TJ, et al. Management of hepatitis B: Summary of a clinical research workshop. Hepatology 2007;45:1056-75 (Pubitemid 46646501)
58. Schalm SW, Heathcote J, Cianciara J, et al. Lamivudine and alpha interferon combination treatment of patients with chronic hepatitis B infection: A randomised trial. Gut 2000;46:562-8 (Pubitemid 30305823)
59. Sanantonio T, Niro GA, Sinisi E, et al. Lamivudine/interferon combination therapy in anti-HBe positive chronic hepatitis B: A controlled pilot study. J Hepatol 2002;36:799-804 (Pubitemid 35177410)
60. Piccolo P, Lenci I, Demelia L, et al. A randomized controlled trial of pegylated interferon-alpha2a plus adefovir dipivoxil for hepatitis B e antigen-negative chronic hepatitis B. Antivir Ther 2009;14:1165-74
61. Wang LC, Chen EQ, Cao J, et al. De novo combination of lamivudine and adefovir versus entecavir monotherapy for the treatment of naive HBeAg-negative chronic hepatitis B patients. Hepatol Int 2011; Epub ahead of print
62. Liaw YF, Sheen IS, Lee CM, et al. Tenofovir disoproxil fumarate (TDF), emtricitabine/TDF and entecavir in patients with decompensated chronic hepatitis B liver disease. Hepatology 2011;53:62-72
63. Lok AS, Zoulim F, Locarnini S, et al. Hepatitis B Virus Drug Resistance Working Group. Antiviral drug-resistant HBV: Standardization of nomenclature and assays and recommendations for management. Hepatology 2007;46:254-65 (Pubitemid 47171942)
64. Ghany MG, Doo EC. Antiviral resistance and hepatitis B therapy. Hepatology 2009;49(5 Suppl):S174-84
65. Kwon H, Lok AS. Hepatitis B therapy. Nat Rev Gastroenterol Hepatol 2011;8:275-84
66. Sherman M, Yurdaydin C, Sollano J, et al. AI463026 BEHoLD Study Group. Entecavir for treatment of lamivudine-refractory, HBeAg-positive chronic hepatitis B. Gastroenterology 2006;130:2039-49 (Pubitemid 43816960)
67. Sherman M, Yurdaydin C, Simsek H, et al. AI463026 Benefits of Entecavir for Hepatitis B Liver Disease (BEHoLD) Study Group. Entecavir therapy for lamivudine-refractory chronic hepatitis B: Improved virological, biochemical and serology outcomes through 96 weeks. Hepatology 2008;48:99-108 (Pubitemid 351975535)
68. Reijnders JG, Deterding K, Petersen J, et al. VIRGIL Surveillance Study Group. Antiviral effect of entecavir in chronic hepatitis B: Influence of prior exposure to nucleos(t)ide analogues. J Hepatol 2010;52:493-500
69. van Bommel F, de Man RA, Wedemeyer H, et al. Long-term efficacy of tenofovir monotherapy for hepatitis B virus-monoinfected patients after failure of nucleoside/nucleotide analogues. Hepatology 2010;51:73-80
70. Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, et al. Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic Hepatitis B. N Engl J Med 2005;352:2673-81 (Pubitemid 41007822)
71. Villet S, Pichoud C, Billioud G, et al. Impact of hepatitis B virus rtA181V/T mutants on hepatitis B treatment failure. J Hepatol 2008;48:747-55
72. Heo NY, Lim YS, Lee HC, et al. Lamivudine plus adefovir or entecavir for patients with chronic hepatitis B resistant to lamivudine and adefovir. J Hepatol 2010;53:449-54
73. Brunelle MN, Jacquard AC, Pichoud C, et al. Susceptibility to antivirals of a human HBV strain with mutations conferring resistance to both lamivudine and adefovir. Hepatology 2005;41:1391-8 (Pubitemid 40770292)
74. Leemans WF, Niesters HG, van der Eijk AA, et al. Selection of an entecavir-resistant mutant despite prolonged hepatitis B virus DNA suppression, in a chronic hepatitis B patient with preexistent lamivudine resistance: Successful rescue therapy with tenofovir. Eur J Gastroenterol Hepatol 2008;20:773-7
75. Kobashi H, Fujioka S, Kawaguchi M, et al. Two cases of development of entecavir resistance during entecavir treatment for nucleoside-naive chronic hepatitis B. Hepatol Int 2009;3:403-10
76. Kau A, Vermehren J, Sarrazin C. Treatment predictors of a sustained virological response in hepatitis B and C. J Hepatol 2008;49:634-51 A systemic review of the predictors of the response to either interferon-based or nucleos(t)ide analogues therapies for CHB patients.
77. Iloeje UH, Yang HI, Su J, et al. Predicting liver cirrhosis risk based on the level of circulating hepatitis B viral load. Gastroenterology 2006;130:678-86 (Pubitemid 43374518)
78. Chen CJ, Yang HI, Su J, et al. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA 2006;295:65-73 (Pubitemid 43042691)
79. Lin CL, Kao JH. Hepatitis B viral factors and clinical outcomes of chronic hepatitis B. J Biomed Sci 2008;15:137-45
80. Mommeja-Marin H, Mondou E, Blum MR, Rousseau F. Serum HBV DNA as a marker of efficacy during therapy for chronic HBV infection: Analysis and review of the literature. Hepatology 2003;37:1309-19 (Pubitemid 36667310)
81. Perrillo RP, Lai CL, Liaw YF, et al. Predictors of HBeAg loss after lamivudine treatment for chronic hepatitis B. Hepatology 2002;36:186-94 (Pubitemid 34700777)
82. Zeuzem S, Gane E, Liaw YF, et al. Baseline characteristics and early on-treatment response predict the outcomes of 2 years of telbivudine treatment of chronic hepatitis B. J Hepatol 2009;51:11-20
83. Bonino F, Marcellin P, Lau GK, et al. Peginterferon alfa-2a HBeAg-negative chronic hepatitis B study group. Predicting response to peginterferon alpha-2a, lamivudine and the two combined for HBeAg-negative chronic hepatitis B. Gut 2007;56:699-705 (Pubitemid 46662938)
84. Lim SG, Marcellin P, Tassopoulos N, et al. Clinical trial: Effects of adefovir dipivoxil therapy in Asian and Caucasian patients with chronic hepatitis B. Aliment Pharmacol Ther 2007;26:1419-28 (Pubitemid 350045604)
85. Tseng TC, Yu ML, Liu CJ, et al. Impact of host and viral factors on HBeAg-positive chronic hepatitis B patients receiving peginterferon alfa-2a therapy. Antivir Ther 2011 (In press)
86. Nguyen T, Desmond P, Locarnini S. The role of quantitative hepatitis B serology in the natural history and management of chronic hepatitis B. Hepatol Int 2009;3:S5-15
87. Thompson AJV, Nguyen T, Iser D, et al. Serum hepatitis B surface antigen and hepatitis B e antigen titers: Disease phase influences correlation with viral load and intrahepatic hepatitis B virus markers. Hepatology 2010;51:1933-44
88. Jaroszewicz J, Serrano BC, Wursthorn K, et al. Hepatitis B surface antigen (HBsAg) levels in the natural history of hepatitis B virus (HBV)-infection: A European perspective. J Hepatol 2010;52:514-22
89. Su TH, Hsu CS, Chen CL, et al. Serum hepatitis B surface antigen concentration correlates with HBV DNA level in patients with chronic hepatitis B. Antivir Ther 2010;15:1133-9
90. Sonneveld MJ, Rijckborst V, Boucher CA, et al. Prediction of sustained response to peginterferon alfa-2b for hepatitis B e antigen-positive chronic hepatitis B using on-treatment hepatitis B surface antigen decline. Hepatology 2010;52:1251-7
91. Rijckborst V, Hansen BE, Cakaloglu Y, et al. Early on-treatment prediction of response to peginterferon alfa-2a for HBeAg-negative chronic hepatitis B using HBsAg and HBV DNA levels. Hepatology 2010;52:454-61
92. Lee JM, Ahn SH, Kim HS, et al. Quantitative hepatitis B surface antigen and hepatitis B e antigen titers in prediction of treatment response to entecavir. Hepatology 2011;53:1486-93
93. Fried MW, Piratvisuth T, Lau GK, et al. HBeAg and hepatitis B virus DNA as outcome predictors during therapy with peginterferon alfa-2a for HBeAg-positive chronic hepatitis B. Hepatology 2008;47:428-34
94. Lin CL, Kao JH. The clinical implications of hepatitis B virus genotype: Recent advances. J Gastroenterol Hepatol 2011;26(Suppl 1):123-30
95. Hou J, Schilling R, Janssen HLA. Molecular characteristics of hepatitis B virus genotype A confer a higher response to interferon treatment. J Hepatol 2001;34(Suppl 1):15
96. Wai CT, Chu CJ, Hussain M, Lok AS. HBV genotype B is associated with better response to interferon therapy in HBeAg(+) chronic hepatitis than genotype C. Hepatology 2002;36:1425-30 (Pubitemid 35403533)
97. Erhardt A, Blondin D, Hauck K, et al. Response to interferon alfa is hepatitis B virus genotype dependent: Genotype A is more sensitive to interferon than genotype D. Gut 2005;54:1009-13 (Pubitemid 40873918)
98. Marcellin P, Bonino F, Lau GK, et al. Peginterferon alfa-2a in HBeAg-negative Chronic Hepatitis B Study Group. Sustained response of hepatitis B e antigen-negative patients 3 years after treatment with peginterferon alpha-2a. Gastroenterology 2009;136:2169-79
99. Wiegand J, Hasenclever D, Tillmann HL. Should treatment of hepatitis B depend on hepatitis B virus genotypes? A hypothesis generated from an explorative analysis of published evidence. Antivir Ther 2008;13:211-20 A meta-analysis addressing whether the determination of HBV genotype has a substantial impact on the selection of antiviral treatments. (Pubitemid 351535372)
100. Buster EH, Hansen BE, Lau GK, et al. Factors that predict response of patients with hepatitis B e antigen-positive chronic hepatitis B to peginterferon-alfa. Gastroenterology 2009;137:2002-9 A study using pooled data from two largest global trials of HBeAg-positive patients to determine the predictors of response to pegylated interferon.
101. Chien RN, Yeh CT, Tsai SL, et al. Determinants for sustained HBeAg response to lamivudine therapy. Hepatology 2003;38:1267-73
102. Yuen MF, Wong DK, Sablon E, et al. Hepatitis B virus genotypes B and C do not affect the antiviral response to lamivudine. Antivir Ther 2003;8:531-4 (Pubitemid 38057098)
103. Chan HL, Wong ML, Hui AY, et al. Hepatitis B virus genotype has no impact on hepatitis B e antigen seroconversion after lamivudine treatment. World J Gastroenterol 2003;9:2695-7 (Pubitemid 38054442)
104. Buti M, Cotrina M, Valdes A, et al. Is hepatitis B virus subtype testing useful in predicting virological response and resistance to lamivudine? J Hepatol 2002;36:445-6 (Pubitemid 34194808)
105. Westland C, Delaney W IV, Yang H, et al. Hepatitis B virus genotypes and virologic response in 694 patients in phase III studies of adefovir dipivoxil. Gastroenterology 2003;125:107-16 (Pubitemid 36799112)
106. Hou J, Yin YK, Xu D, et al. Telbivudine versus lamivudine in Chinese patients with chronic hepatitis B. Results at 1 year of a randomized, double-blind trial. Hepatology 2008;47:447-54 (Pubitemid 351280712)
107. Hsieh TH, Tseng TC, Liu CJ, et al. Hepatitis B virus genotype B has an earlier emergence of lamivudine resistance than genotype C. Antivir Ther 2009;14:1157-63
108. Tseng TC, Liu CJ, Kao JH. Implications of hepatitis B virus genomic variations on treatment outcomes. Curr Pharmacogenomics Personalized Med 2010;8:280-8
109. Tseng TC, Liu CJ, Wang CC, et al. Association of baseline viral factors with response to lamivudine therapy in chronic hepatitis B patients with high serum alanine aminotransferase levels. Antivir Ther 2009;14:203-10
110. Yuen MF, Fong DY, Wong DK, et al. Hepatitis B virus DNA levels at week 4 of lamivudine treatment predict the 5-year ideal response. Hepatology 2007;46:1695-703
111. Shin JW, Park NH, Jung SW, et al. Clinical usefulness of sequential hepatitis B virus DNA measurement (the roadmap concept) during adefovir treatment in lamivudine-resistant patients. Antivir Ther 2009;14:181-6
112. Lee JM, Park JY, Kim do Y, et al. Long-term adefovir dipivoxil monotherapy for up to 5 years in lamivudine-resistant chronic hepatitis B. Antivir Ther 2010;15:235-41
113. Leung N, Peng CY, Hann HW, et al. Early hepatitis B virus DNA reduction in hepatitis B e antigen-positive patients with chronic hepatitis B: A randomized international study of entecavir versus adefovir. Hepatology 2009;49:72-9
114. Nguyen MH, Keeffe EB. Chronic hepatitis B: Early viral suppression and long-term outcomes of therapy with oral nucleos(t)ides. J Viral Hepat 2009;16:149-55
115. Keeffe EB, Zeuzem S, Koff RS, et al. Report of an international workshop: Roadmap for management of patients receiving oral therapy for chronic hepatitis B. Clin Gastroenterol Hepatol 2007;5:890-7 Using on-treatment HBV DNA reduction at weeks 12 and 24 to make management decisions in CHB patients treated with nucleos(t) ide analogues. (Pubitemid 47127032)
116. Brunetto MR, Moriconi F, Bonino F, et al. Hepatitis B virus surface antigen levels: A guide to sustained response to peginterferon alfa-2a in HBeAg-negative chronic hepatitis B. Hepatology 2009;49:1141-50
117. Moucari R, Mackiewicz V, Lada O, et al. Early serum HBsAg drop: A strong predictor of sustained virological response to pegylated interferon alfa-2a in HBeAg-negative patients. Hepatology 2009;49:1151-7
118. Moucari R, Lada O, Marcellin P. Chronic hepatitis B: Back to the future with HBsAg. Expert Rev Anti Infect Ther 2009;7:633-6
119. Moucari R, Marcellin P. Quantification of hepatitis B surface antigen: A new concept for the management of chronic hepatitis B. Liver Int 2011;31(Suppl 1):122-8
120. Reijnders JG, Rijckborst V, Sonneveld MJ, et al. Kinetics of hepatitis B surface antigen differ between treatment with peginterferon and entecavir. J Hepatol 2011;54:449-54
121. Frodsham AJ. Host genetics and the outcome of hepatitis B viral infection. Transpl Immunol 2005;14:183-6 (Pubitemid 40848524)
122. Kamatani Y, Wattanapokayakit S, Ochi H, et al. A genome-wide association study identifies variants in the HLA-DP locus associated with chronic hepatitis B in Asians. Nat Genet 2009;41:591-5
123. Thomas DL, Thio CL, Martin MP, et al. Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. Nature 2009;461:798-801
124. Ge D, Fellay J, Thompson AJ, et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 2009;461:399-401
125. Huang HH, Shih WL, Li YH, et al. Hepatitis B viraemia: Its heritability and association with common genetic variation in the interferon gamma signalling pathway. Gut 2011;60:99-107
126. Chan HL, Tse AM, Zhang MD, et al. Genetic polymorphisms of interleukin-1-beta in association with sustained response to anti-viral treatment in chronic hepatitis B in Chinese. Aliment Pharmacol Ther 2006;23:1703-11 (Pubitemid 43846413)
127. King JK, Yeh SH, Lin MW, et al. Genetic polymorphisms in interferon pathway and response to interferon treatment in hepatitis B patients: A pilot study. Hepatology 2002;36:1416-24 (Pubitemid 35403532)
128. Wu X, Zhu X, Zhu S, et al. A pharmacogenetic study of polymorphisms in interferon pathway genes and response to interferon-alpha treatment in chronic hepatitis B patients. Antiviral Res 2009;83:252-6
129. Kao JH. Appropriate use of interferon for treatment of chronic hepatitis B. Hepatol Res 2007;37:S47-54
130. Rijckborst V, Sonneveld MJ, Janssen HL. Review article: Chronic hepatitis B - anti-viral or immunomodulatory therapy? Aliment Pharmacol Ther 2011;33:501-13
131. Shamliyan TA, Johnson JR, Macdonald R, et al. Systematic review of the literature on comparative effectiveness of antiviral treatments for chronic hepatitis B infection. J Gen Intern Med 2011;26:326-39